Rescuing the cerebral ischemia-mediated brain damage: MiRNA-107 attenuates cerebral ischemia-mediated brain damage via down regulation of its target gene, 12/June/2015, 9.48 pm

Interleukin-based therapy for Age-associated dementia and Alzheimer’s disease (AD): IL-6 increases the expression of AGE receptor 1 (AGER1), the longevity-promoting gene Sirtuin-1 and decreases advanced glycation end products (AGEs) via down regulation of its target gene, 12/June/2015, 8.43 pm
June 12, 2015
Natural product-based therapy for metastatic breast cancer: I3C, a natural compound found in Broccoli & Brussels, blocks bone metastasis of mammary cancer via down regulation of its target gene, 12/June/2015, 10.51 pm
June 12, 2015
Show all

A recent study from the Department of Cancer Biology and Pharmacology, University of Illinois College of Medicine at Peoria, Peoria, IL, USA shows that “Post-transcriptional inactivation of matrix metalloproteinase-12 after focal cerebral ischemia attenuates brain damage.” This study was published in the 8 May 2015 issue of the Journal “Sci Reports” by Prof Veeravalli KK, Chelluboina B and Others.

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMDreports that: Rescuing the cerebral ischemia-mediated brain damage: MiRNA-107 attenuates cerebral ischemia-mediated brain damage via down regulation of its target gene

Idea Proposed/Formulated byDr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

CitationBoominathan, Rescuing the cerebral ischemia-mediated brain damage: MiRNA-107 attenuates cerebral ischemia-mediated brain damage via down regulation of its target gene, 12/June/2015, 9.48 pm, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Web: http://genomediscovery.org

Courtesy: When you cite drop us a line at info@genomediscovery.org

Significance: 

Given that: (1)  stroke is the second leading cause of death worldwide in 2011; (2)  11% of total deaths were due to stroke; (3) stroke deaths increased by 10% in the developing world; (3) south asians account for 40% global stroke deaths; (4) the  economic cost spent in europe27 countries for the treatment of stroke was little more than 27 billion euro dollars, while in the united states in 2008 $65.5 billion dollars; and (5) approximately 85% of all stroke deaths are recorded in low- and middle-income countries, there is an urgent need to find:  (i) an effective therapy against stroke; (ii) a cheaper alternative to the existing expensive drugs; and (iii) a side-effect-free natural product-based drug.

This study suggests an miRNA-based therapy for Ischemic Stroke.  MiRNA-107, by decreasing the expression of its target gene, it may: (1) increase the expression of myelin basic protein; (2) decrease the expression of MMP-9 & TNFα; (3) decrease infarct size; (4) promote neuroprotection; and (5) attenuate cerebral ischemia-mediated brain damage.  Thus, pharmacological formulations encompassing “MiRNA-107 activators may be used to treat Ischemic Stroke.

Comments are closed.